Following the science is a key discipline for success. Listen to our CEO, Aron Knickerbocker, and his advice for the next generation in #biotech, including how this principle has guided him throughout his career: https://bit.ly/3YIbVpB #Oncology #BusinessofBiotech Bioprocess Online
Aulos Bioscience’s Post
More Relevant Posts
-
Our lead asset, AU-007, is leveraging IL-2 differently. Hear what makes our #AI -backed approach different on #BusinessofBiotech with Matthew Pillar. https://bit.ly/3YxaZpp #BioTech #Oncology Bioprocess Online
-
Faron has today published its full-year financial #results for the twelve months ended 31 December 2023. You can read the full statement here: https://lnkd.in/d3hnaSma #Faron #biotech #drugdevelopment #oncology
-
-
Immutep Limited shares positive survival data from INSIGHT-003 in 1L #NSCLC. With a median overall survival of 32.9 months and progression-free survival at 12.7 months, and 24-month survival reaching 81%, these results demonstrate significant improvement compared to historical controls. Read: https://bit.ly/3YFXLFi #biotechnology #NSCLC #oncology
-
-
The pioneers in LAG-3 show significant 2+ year 1st-line survival in non-squamous NSCLC. Eftilagimod alpha + Keytruda-- synergy adding this novel MHC Class II agonist, even patients with low/neg PD-L1 expression.
Immutep Limited shares positive survival data from INSIGHT-003 in 1L #NSCLC. With a median overall survival of 32.9 months and progression-free survival at 12.7 months, and 24-month survival reaching 81%, these results demonstrate significant improvement compared to historical controls. Read: https://bit.ly/3YFXLFi #biotechnology #NSCLC #oncology
-
-
Immutep Limited is pleased to share an Investor Update discussing the upcoming TACTI-004 trial & becoming a Phase 3 biotech. The potential for efti combined with KEYTRUDA & chemo is to set a new standard-of-care in #NSCLC Read more here: https://bit.ly/4eRmFb8 #Biotech #Oncology #LCSM #LungCancerAwarenessMonth
-
🌟 Few companies have a story as inspiring as EnGeneIC. From their early days at CSIRO to becoming a biotech leader revolutionising cancer treatment, EnGeneIC’s FDA fast-tracked EDV™ nanocell platform has delivered life-changing results. Breakthroughs include but are not limited to: ✨ A pancreatic cancer patient tumour-free for 30 months—a global first. 🌍 Distribution partnerships across Southeast Asia. 🔬 Expanding their platform to target glioblastoma and osteosarcoma. 🔒 217 global patents securing innovation through 2050 and beyond. 🎥 Watch their exclusive interview with VentureCrowd's CEO Steven Maarbani to learn more about their journey and bold plans for the future. 👉 https://bit.ly/4g1oX8X #VentureCrowd #Biotech #EnGeneIC Always consider the offer documents before investing. Past performance is not a reliable indicator of future performance.
-
ExoProTher eagerly awaits the State-of-the-Art Envision NTA Machine from HYPERION ANALYTICAL We are excited to share that the brand-new, and Israel's first, Nanoparticle Tracking Analysis (NTA) machine of this kind – Envision from Hyperion Analytical LLC, is on the way to ExoProTher’s labs. The Envision will significantly enhance our analytical capabilities and data reliability. Our investment in the HYPERION NTA Envision underscores our commitment to pioneering science and best quality data behind the development of p53 replacement therapy for oncology indications. Watch this space for more updates! #nanoparticletrackinganalysis #innovation #p53replacementtherapy #biotechnology #oncology
-
-
Does #dubai have what it takes to be a #biotechnology Hub? Dr James, an #oncology Drug #development #physician belief so and I concur. His reasons are compelling, but one has to watch or listen to the latest episode to understand his stance and what it takes to start a Biotechnology Company. Link in the comments. #science #biotech #cancer #research
-
In our on-demand Tech Talk, Katharina Krohn, Vice President Global Biobanks, reveals the keys to revolutionizing personal medicine through the use of biobanks. In this webinar, you will discover what you should consider when selecting a type of biobank and how to identify crucial sample data sets. Learn more about: ✅Proper quality control ensures that biospecimens are suitable for their intended use ✅Variables in the pre-analytical phase (collection, processing, and storage) significantly impact sample quality Watch the full on-demand webinar – which is less than 20 minutes - at your convenience. ➡️ https://bit.ly/4996anT #Biospecimen #Biobank #Oncology
-
Catch Szabolcs Nagy, our CEO, at BiotechX EU 2024! Interested in a quick catch-up, or even a more in depth discussion? Reach out to Szabi LinkedIn or send an e-mail to [email protected] to set up a meeting. Looking forward to connect! #biotechxeu #biotechxeuconference #aifordrugdevelopment #simulatedbiology #oncology #turbineai
-
Experienced Clinical Development Professional committed to advancing inclusive medical research and technology across underrepresented patient populations to increase treatment optionality.
2wLove this and greatly enjoyed hearing your advice. Well done and thank you for sharing. 👏